Clinical trials: Head and Neck Cancer Patients
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pralatrexate and oxaliplatin work in treating patients with esophageal, stomach, or gastroesophageal junction cancer that cannot be removed by surgery or has spread from the primary site…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
- Trial name
- NCT01178944
- Testing
- Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Hepato-Biliary Carcinoma in Situ Nos, Pancreatic Cancer
Assessing the Accuracy of Seismofit® as an Estimate of VO2 Peak in Patients With Hepato-pancreato-biliary, Colorectal, and Gastro-oesophageal Cancer
Our study aims to assess the relationship between the Seismofit® derived VO2 peak estimate and CPET-measured VO2 peak in patients who are having CPET as part of their preoperative workup.
- Conditions
- Hepato-Biliary Carcinoma in Situ Nos, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- VERVE (NCT05831488)
- Testing
- Non-Interventional
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Nasopharyngeal Carcinoma (NPC)
Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy
Clinicopathological and genomic data (Next generation sequencing and IHC/CISH) in available tissues were performed in patients with nasopharyngeal carcinoma who participated in a previously conducted randomized phase II study…
- Trial name
- NCT07741110
- Testing
- Next generation sequencing, Immunohistochemistry/CISH
- Volunteers
- 141 people
- Sponsor
- Hellenic Cooperative Oncology Group
Radiation-induced Oral Mucositis, Head and Neck Cancer
Citrus Sinensis Peel Gel for Radiation-Induced Oral Mucositis
This randomized controlled clinical trial aims to evaluate the efficacy of Citrus sinensis peel extract gel in the treatment of radiation-induced oral mucositis in head and neck cancer patients.
- Trial name
- NCT07813923
- Testing
- Citrus sinensis peel extract gel, Conventional supportive treatment
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Device
Comparison of Record in VERITON Camera to the Anger Camera Procedure in Patients Treated by 131-iodine
The aim of this study is to show that the SPECT/CT whole body recording procedure lasting less than or equal to 30 minutes in a VERITON-CT™ camera, can be substituted for the classic procedure, giving at least equivalent…
- Trial name
- VERICATH (NCT05713123)
- Testing
- A SPECT-CT whole body is added in VERITON-CT camera
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Central Hospital, Nancy, France
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Oral Mucositis
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
The purpose of this study is to explore the protective effect and safety of soluble beta-1,3/1,6-glucan compared to placebo in oral mucositis in head and neck patients receiving radiotherapy or chemoradiotherapy.
- Trial name
- NCT00289003
- Testing
- Soluble beta-1,3/1,6-glucan
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Biotec Pharmacon ASA
Head and Neck Cancers
Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers
This is a protocol to collect tissues, blood, and other specimens from patients with malignant or nonmalignant diseases of the head and neck.
- Trial name
- NCT00580203
- Where
- United States
- Volunteers
- 1,468 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Carcinoma
Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy
Background:Although concurrent chemoradiotherapy is effective for improving disease-free survival and overall survival in patients with locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT03045484
- Testing
- Controlled-release oxycodone, Chemoradiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Effect of Exercise in Head and Neck Cancer Patients
Head and neck cancers (HNC) are malignancies originating from the mucosa in the oral cavity, nasopharynx, oropharynx, hypopharynx and larynx.
- Trial name
- EffEx-HN (NCT05256238)
- Testing
- comprehensive supervised exercise program (CSEP)
- Where
- Belgium
- Volunteers
- 133 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Esophageal Adenocarcinoma, Esophageal Cancer
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
- Trial name
- NCT05480384
- Testing
- Nivolumab, Trastuzumab deruxtecan
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Head and Neck Squamous Cell Carcinoma
A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a study to assess how much of the investigational drug, PF-00298804, is in the blood stream over a period of time (called pharmacokinetic tests or PK) in patients with locally advanced head and neck squamous cell…
- Trial name
- NCT01484847
- Testing
- PF-00299804
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Esophageal Cancer
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
There is a need for more effective therapy for patients with esophageal squamous cell carcinoma who developed disease progression after first line therapy. Currently, there is no standard second-line therapy for this disease.
- Trial name
- NCT01806649
- Testing
- BKM120
- Where
- Thailand
- Volunteers
- 5 people
- Sponsor
- Prince of Songkla University
Trismus
Prevention of Trismus During Radiotherapy and Quality of Life in Head and Neck Cancer Patients
Trismus (limited jaw mobility), can occur in patients undergoing radiotherapy to specific areas of the head or neck. Trismus leads to difficulty in eating, swallowing, speech and general mouth hygiene, which all have negative…
- Trial name
- NCT01354548
- Testing
- TheraBite® Jaw Motion Rehabilitation System™
- Where
- 2 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- University Hospital, Linkoeping
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary…
- Conditions
- Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm
- Trial name
- NCT06915727
- Testing
- Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Esophageal Cancer
Effects of a "Walk, Eat, & Breathe" Nursing Intervention For Patients With Esophageal Cancer
The purpose of this stratified randomized controlled trial (RCT) is to test the effects of Walk, Eat, \& Breathe on preserving patients' nutritional status, functional walking capacity, pulmonary function, and emotional…
- Trial name
- NCT02850172
- Testing
- Walk, Eat, & Breathe
- Where
- Taiwan
- Volunteers
- 144 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Head and Neck Cancer (H&N)
Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors
Urokinase plasminogen activator receptor (uPAR), the cell-surface receptor for its ligand uPA, plays a critical role in regulating cell migration and invasion-key drivers of cancer progression.
- Conditions
- Breast Cancer, Head and Neck Cancer (H&N), Pancreatic Cancer, Glioma
- Trial name
- NCT07639970
- Testing
- [⁶⁸Ga]Ga-HT547 and [¹⁷⁷Lu]Lu-HT547
- Volunteers
- 20 people
- Sponsor
- Hua Pang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.